方盛制药(603998.SH)：洛索洛芬钠凝胶贴膏获得《药品注册证书》

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for the production of Loxoprofen Sodium Gel Patch, which is now approved for manufacturing [1] Group 1: Product Information - Loxoprofen Sodium Gel Patch is indicated for the treatment of osteoarthritis, muscle pain, and swelling pain after trauma, providing anti-inflammatory and analgesic effects [1] - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid class, known for its significant analgesic effects [1] - The product is developed by LEADCHEMICAL CO., LTD. and is one of the leading analgesic drugs in the Chinese market in terms of long-term sales [1] Group 2: Mechanism of Action - The mechanism of action involves the inhibition of prostaglandin synthesis through the suppression of cyclooxygenase [1] - Loxoprofen Sodium acts as a prodrug, which is converted into its active metabolite trans-OH after transdermal absorption [1]